Akero Therapeutics Inc
AKRO
ISIN null / Valor 48188266
Akero Therapeutics Inc
UMushroom community rating:
About company
Akero Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Boston that develops engineered FGF21‑based biologics aimed at treating chronic metabolic liver diseases, principally nonalcoholic steatohepatitis (NASH) and related metabolic disorders such as type 2 diabetes; its lead programs are FGF21 analogs designed to alter lipid and glucose metabolism and address liver injury and fibrosis and are being advanced through clinical trials. The company has no approved products and focuses its resources on clinical development, regulatory strategy and partnering or financing to support trials and potential commercialization.
Summarized from source with an LLMView SourceSector: TechnologyKey figures
Performance
Volatility
4499 M
Market cap (USD)
Daily traded volume (Shares)
28.03 / 27.54
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
